Naheed Kurji

Contributor   in
Industry Trends   Emerging Technologies  

Naheed is the President and CEO of Cyclica, a Toronto-based, ventured-backed biotech that is driving drug discovery by empowering scientists in pharma with a cloud-based and AI-augmented platform to enhance how they design, screen, and personalize medicines.

tags:   Artificial Intelligence     Biopharma news     In Silico     Machine Learning     Small Molecules    

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

Presenting a New Paradigm for Drug Discovery: Combining Computational Biophysics and AI through MatchMaker

   3364
Presenting a New Paradigm for Drug Discovery: Combining Computational Biophysics and AI through MatchMaker

In this Special Perspective, our fourth in an ongoing series, we will be presenting MatchMaker™, a novel deep proteome screening technology that we have developed and validated over the past 2 years to identify DTIs. MatchMaker builds on Cyclica’s passions of combining protein, chemistry, and genomic data, and augmenting it with high performance computing and algorithm development supported on the cloud.